Form 8-K - Current report:
SEC Accession No. 0000950170-21-003893
Filing Date
2021-11-10
Accepted
2021-11-10 07:02:39
Documents
13
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrx-20211110.htm   iXBRL 8-K 59668
2 EX-99.1 tcrx-ex99_1.htm EX-99.1 193609
  Complete submission text file 0000950170-21-003893.txt   384770

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tcrx-20211110_pre.xml EX-101.PRE 10938
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tcrx-20211110.xsd EX-101.SCH 2483
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tcrx-20211110_lab.xml EX-101.LAB 13342
6 EXTRACTED XBRL INSTANCE DOCUMENT tcrx-20211110_htm.xml XML 4707
Mailing Address 830 WINTER STREET WALTHAM MA 02451
Business Address 830 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 211394347
SIC: 2836 Biological Products, (No Diagnostic Substances)